Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

  1. Cabrero, M.
  2. Martin, A.
  3. Briones, J.
  4. Gayoso, J.
  5. Jarque, I.
  6. López, J.
  7. Grande, C.
  8. Heras, I.
  9. Arranz, R.
  10. Bernal, T.
  11. Perez-Lopez, E.
  12. López-Godino, O.
  13. Conde, E.
  14. Caballero, D.
Revue:
Biology of Blood and Marrow Transplantation

ISSN: 1523-6536,  1083-8791

Année de publication: 2017

Volumen: 23

Número: 1

Pages: 53-59

Type: Article

DOI: 10.1016/J.BBMT.2016.10.003 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus